Tandem Diabetes Care (LTS:0M0F) Research & Development: $189 Mil (TTM As of Mar. 2026)


LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
67 GF Score
Price $15.87
GF Value $29.23
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Research & Development?

Tandem Diabetes Care LTS:0M0F +0.95% 67 Research & Development is $189 Mil as of Mar. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 67/100 and a GF Value™ of $29.23 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tandem Diabetes Care's Research & Development for the three months ended in Mar. 2026 was $46 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $189 Mil.

Tandem Diabetes Care  (LTS:0M0F) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tandem Diabetes Care Research & Development Related Terms

Tandem Diabetes Care Research & Development Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Research & Development Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.05 170.15 248.42 198.88 268.33

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.43 48.12 48.72 46.07 46.04
LTS:0M0F
67GF Score
Tandem Diabetes Care Inc LTS:0M0F
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $189 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $189 Mil mean?
Tandem Diabetes Care (LTS:0M0F) has a Research & Development of $189 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Research & Development too high?
Tandem Diabetes Care's current Research & Development is $189 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Research & Development compare to ATEC and BFLY?
Tandem Diabetes Care's Research & Development of $189 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Research & Development is $189 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.23, compared to a current price of $15.87 — trading 45.7% below its estimated fair value. The current Research & Development is $189 Mil. Tandem Diabetes Care's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Research & Development is $189 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $15.87 is trading 45.7% below its estimated GF Value™ of $29.23. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • Research & Development: $189 Mil
  • GF Value™: $29.23 vs. price of $15.87 (45.7% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
67GF Score

Get the complete analysis for LTS:0M0F

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.87
Price
$29.23
GF Value